Diane-35
PreclinicalSmall molecule
Diane-35 is one of 51 small molecule programs targeting Polycystic Ovary Syndrome. It is currently in Preclinical.
1
Indications
3
Total Trials
1
Active Trials
50
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
72 competitors in Polycystic Ovary Syndrome
#DrugCompanyPhaseTrials
1Glucophage
EMD SeronoApproved
Femara
NovartisApproved
Actos
TakedaApproved
Myrbetriq
AstellasApproved
Evista
Eli LillyApproved
Onglyza
AstraZenecaApproved
Calciferol
Jazz PharmaceuticalsApproved
Alli
EEngelhard Arzneimittel GmbH & Co.KG
Approved
Invokana
WWim Janssens
Approved
Tradjenta
Boehringer IngelheimApproved
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Diane-35. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Preclinical[1]
- Company
- XXiaojun Chen